Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Reducing expression of the fetal hemoglobin (HbF) repressor BCL11A leads to a simultaneous increase in γ-globin expression and reduction in β-globin expression. Thus, there is interest in targeting BCL11A as a treatment for β-hemoglobinopathies, including sickle cell disease (SCD) and β-thalassemia. Here, we found that using optimized shRNAs embedded within an miRNA (shRNAmiR) architecture to achieve ubiquitous knockdown of BCL11A profoundly impaired long-term engraftment of both human and mouse hematopoietic stem cells (HSCs) despite a reduction in nonspecific cellular toxicities. BCL11A knockdown was associated with a substantial increase in S/G2-phase human HSCs after engraftment into immunodeficient (NSG) mice, a phenotype that is associated with HSC exhaustion. Lineage-specific, shRNAmiR-mediated suppression of BCL11A in erythroid cells led to stable long-term engraftment of gene-modified cells. Transduced primary normal or SCD human HSCs expressing the lineage-specific BCL11A shRNAmiR gave rise to erythroid cells with up to 90% reduction of BCL11A protein. These erythrocytes demonstrated 60%-70% γ-chain expression (vs. < 10% for negative control) and a corresponding increase in HbF. Transplantation of gene-modified murine HSCs from Berkeley sickle cell mice led to a substantial improvement of sickle-associated hemolytic anemia and reticulocytosis, key pathophysiological biomarkers of SCD. These data form the basis for a clinical trial application for treating sickle cell disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an erythroid-specific knockdown of BCL11A delivered by a lentiviral-encoded, microRNA-adapted short hairpin RNA molecule has been shown to reactivate the γ-globin gene and is in early clinical development.[17][18][19]”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Self-citationBCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Self-citationUda, M., Galanello, R., Sanna, S., Lettre, G., Sankaran, V. G., Chen, W., Usala, G., Busonero, F., Maschio, A., Albai, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711566105 · Cited by 672
Self-citationAn Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Self-citationCorrection of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
The β-globin nuclear compartment in development and erythroid differentiation
Palstra, R.-J., Tolhuis, B., Splinter, E., Nijmeijer, R., Grosveld, F., & de Laat, W. (2003) · Nature Genetics · doi:10.1038/ng1244 · Cited by 559
Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Developmental and species-divergent globin switching are driven by BCL11A
Sankaran, V. G., Xu, J., Ragoczy, T., Ippolito, G. C., Walkley, C. R., Maika, S. D., Fujiwara, Y., Ito, M., Groudine, M., Bender, M. A., et al. (2009) · Nature · doi:10.1038/nature08243 · Cited by 379
Self-citationWalters, M. C., Storb, R. F., Patience, M., Leisenring, W. M., Taylor, T., Sanders, J. E., Buchanan, G. E., Rogers, Z. R., Dinndorf, P. A., Davies, S. C., et al. (2000) · PubMed · doi:10.1182/blood.v95.6.1918 · Cited by 361
Xu, J., Sankaran, V. G., Ni, M., Menne, T. F., Puram, R. V., Kim, W., & Orkin, S. H. (2010) · Genes & Development · doi:10.1101/gad.1897310 · Cited by 361
Self-citation
Cited by
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029392 · Cited by 449
Self-citationGene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Recent Advances in the Treatment of Sickle Cell Disease
Salinas Cisneros, G., & Thein, S. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00435 · Cited by 193
“BCL11A also has roles in lymphoid and neurological development but gene-editing for SCD exploits the erythroid-specific enhancers in intron 2 of the gene (Bauer et al., 2013; Brendel et al., 2016).”
BackgroundInduction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Antoniani, C., Meneghini, V., Lattanzi, A., Felix, T., Romano, O., Magrin, E., Weber, L., Pavani, G., El Hoss, S., Kurita, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811505 · Cited by 194
Therapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 181
Fu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., Yang, F., Hsiao, S., Jiang, Y., Wang, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01906-z · Cited by 181
Sickle Cell Anemia and Its Phenotypes
Williams, T., & Thein, S. L. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021320 · Cited by 201
“The best established is the induction of HbF synthesis, which holds particular promise because there is plentiful evidence of efficacy from clinical and epidemiological studies.”
BackgroundInfluentialChang, K.-H., Smith, S. E., Sullivan, T., Chen, K., Zhou, Q., West, J. A., Liu, M., Liu, Y., Vieira, B. F., Sun, C., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.009 · Cited by 155
“Another lenti-based short hairpin RNA (shRNA) gene therapy approach that selectively knock downs B cell lymphoma/leukemia 11A (BCL11A), one of the key suppressors of anti-sickling fetal g-globin, in erythroid cells is actively under investigation.(21,22) Other novel gene therapy strategies such as correcting the sickl…”
BackgroundMethodInfluentialGene Therapy for β-Hemoglobinopathies
Cavazzana, M., Antoniani, C., & Miccio, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.024 · Cited by 124
Psatha, N., Reik, A., Phelps, S., Zhou, Y., Dalas, D., Yannaki, E., Levasseur, D. N., Urnov, F. D., Holmes, M. C., & Papayannopoulou, T. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.003 · Cited by 115
Emerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Self-citationWake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies
Wienert, B., Martyn, G. E., Funnell, A. P. W., Quinlan, K. G. R., & Crossley, M. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.09.004 · Cited by 115
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
“One approach in preclinical development utilizes HBB LCR-driven expression of a microRNA-adapted shRNA targeting BCL11A (Brendel et al, 2016).”
BackgroundSelf-citationHumbert, O., Radtke, S., Samuelson, C., Carrillo, R. R., Perez, A. M., Reddy, S. S., Lux, C., Pattabhi, S., Schefter, L. E., Negre, O., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw3768 · Cited by 111
Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases
Poletti, V., & Mavilio, F. (2021) · Viruses · doi:10.3390/v13081526 · Cited by 120
“Post-transcriptional down-regulation of BCL11A can be restricted to the erythroblastic progeny of HSCs by expressing a synthetic regulatory RNA consisting of an optimized shRNA sequence embedded within a miR scaffold (shmiR) under the control of the erythroid-specific combination of a β-globin promoter and β-LCR minim…”
BackgroundGene therapy for sickle cell disease: moving from the bench to the bedside
Abraham, A., & Tisdale, J. F. (2021) · Blood · doi:10.1182/blood.2019003776 · Cited by 111
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Magrin, E., Miccio, A., & Cavazzana, M. (2019) · Blood · doi:10.1182/blood.2019000949 · Cited by 114
Gene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
“In a current open gene therapy trial (NCT03282656, Table 1), the HbF induction strategy is based on introduction of shRNA targeting BCL11A suppression in erythroid cells derived from HSCs for the purpose of increasing γ-globin and reducing mutant βS globin expression (58).”
BackgroundArtificial miRNAs as therapeutic tools: Challenges and opportunities
Kotowska‐Zimmer, A., Pewińska, M., & Olejniczak, M. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1640 · Cited by 101
BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases
Yin, J., Xie, X., Ye, Y., Wang, L., & Che, F. (2019) · Bioscience Reports · doi:10.1042/bsr20190604 · Cited by 77
Brendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
“Significant downregulation of BCL11A in erythroid cells leads to sustained reactivation of g-globin, the production of HbF, reduced polymerization of sicklecontaining hemoglobin, and significant mitigation of the hematologic effects of SCD.35 Our strategy and vector configuration underwent several stages of developmen…”
BackgroundMethodResultSelf-citationKhosravi, M. A., Abbasalipour, M., Concordet, J., Berg, J. V., Zeinali, S., Arashkia, A., Azadmanesh, K., Buch, T., & Karimipoor, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.042 · Cited by 76
BCL11A enhancer–edited hematopoietic stem cells persist in rhesus monkeys without toxicity
Demirci, S., Zeng, J., Wu, Y., Uchida, N., Shen, A. H., Pellin, D., Gamer, J., Yapundich, M., Drysdale, C., Bonanno, J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140189 · Cited by 66
“BCL11A plays critical roles in B-lymphocyte maturation and HSC self-renewal (30-32).”
BackgroundSelf-citationYen, J., Fiorino, M., Liu, Y., Paula, S., Clarkson, S., Quinn, L., Tschantz, W. R., Klock, H., Guo, N., Russ, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34601-6 · Cited by 67
Gene Therapy for Hemoglobinopathies
Cavazzana, M., & Mavilio, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.122 · Cited by 71
Lamsfus‐Calle, A., Daniel-Moreno, A., Antony, J. S., Epting, T., Heumos, L., Baskaran, P., Admard, J., Casadei, N., Latifi, N., Siegmund, D. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66309-x · Cited by 66
Gene Therapy For Beta-Thalassemia: Updated Perspectives
Karponi, G., & Ζώγας, Ν. (2019) · The Application of Clinical Genetics · doi:10.2147/tacg.s178546 · Cited by 60
“Indeed, erythroid-specific BCL11A knockdown has previously been shown to support high-level and sustained reactivation of gamma-globin in Κ562 cells(78) and human HSCs(77) and also effectively bypass the engrafting inability of HSCs with ubiquitous BCL11A downregulation.(77) Alternatively, disrupting the binding site”
BackgroundGene Therapy Approaches to Hemoglobinopathies
Ferrari, G., Cavazzana, M., & Mavilio, F. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.010 · Cited by 56
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
Demirci, S., Leonard, A. K., Essawi, K., & Tisdale, J. F. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.010 · Cited by 61
Lux, C. T., Pattabhi, S., Berger, M. P., Nourigat, C., Flowers, D. A., Nègre, O., Humbert, O., Yang, J., Lee, C., Jacoby, K., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.008 · Cited by 53
Cruz, L. J., van Dijk, T., Vepris, O., Li, T. M. W. Y., Schomann, T., Baldazzi, F., Kurita, R., Nakamura, Y., Grosveld, F. G., Philipsen, S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120580 · Cited by 53
Samuelson, C., Radtke, S., Zhu, H., Llewellyn, M. J., Fields, E., Cook, S. M., Huang, M.-L. W., Jerome, K. R., Kiem, H., & Humbert, O. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.008 · Cited by 54
“Initial attempts to do this by pan-repression of expression across all hematopoietic lineages resulted in engraftment failure and ineffective erythropoiesis in modified cells.(24,25) Later discoveries demonstrated no such impairments where an erythroid-specific enhancer motif was instead targeted within the BCL11A int…”
BackgroundStrict in vivo specificity of the Bcl11a erythroid enhancer
Smith, E. C., Luc, S., Croney, D. M., Woodworth, M. B., Greig, L. C., Fujiwara, Y., Nguyen, M., Sher, F., Macklis, J. D., Bauer, D. E., et al. (2016) · Blood · doi:10.1182/blood-2016-08-736249 · Cited by 48
Self-citationAntoniani, C., Romano, O., & Miccio, A. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0192 · Cited by 59
Gene Therapy for Hemoglobinopathies
Leonard, A. K., Tisdale, J. F., & Bonner, M. A. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.008 · Cited by 55
Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives
de Azevedo, J. T. C., & Malmegrim, K. C. R. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.04.012 · Cited by 51
Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?
Leonard, A., Tisdale, J., & Abraham, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16437 · Cited by 45
“Erythroid-specific expression of microRNA-adapted shRNAs (shRNAmiR) targetting BCL11A effectively induced HbF in human erythroid cells derived from transduced HSCs (Brendel et al., 2016) and is currently being investigated (NCT03282656).”
BackgroundInfluentialHumbert, O., Peterson, C. W., Norgaard, Z. K., Radtke, S., & Kiem, H.-P. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.005 · Cited by 43
Gene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 42
Genetic therapies for sickle cell disease
Esrick, E. B., & Bauer, D. E. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.014 · Cited by 41
Self-citationBrendel, C., Río, P., & Verhoeyen, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113711 · Cited by 41
Self-citationHematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies
Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., Tisdale, J. F., & Uchida, N. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.001 · Cited by 45
CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery
Lin, Y., Feng, K.-K., Lu, J.-Y., Le, J., Li, W.-L., Zhang, B., Li, C., Song, X.-H., Tong, L.-W., & Shao, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.028 · Cited by 42
Pharmacological and molecular approaches for the treatment of β‐hemoglobin disorders
Lohani, N., Bhargava, N., Munshi, A., & Ramalingam, S. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26292 · Cited by 40
“Furthermore, BCL11A knockdown reactivated 60–70% γ-globin expression and associated increase in HbF synthesis (Brendel et al., 2016).”
BackgroundMolecular Medicine: Found in Translation
Orkin, S. H. (2021) · Med · doi:10.1016/j.medj.2020.12.011 · Cited by 39
Self-citationHow I treat sickle cell disease with hematopoietic cell transplantation
Stenger, E. O., Shenoy, S. S., & Krishnamurti, L. (2019) · Blood · doi:10.1182/blood.2019000821 · Cited by 37
Gene therapy and gene editing strategies for hemoglobinopathies
Lidonnici, M. R., & Ferrari, G. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.12.001 · Cited by 37
Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti, L. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2020.551170 · Cited by 37
“Ongoing studies will also address the durability of gene-modified cell engraftment, as well as the long-term risk, if any, of insertional mutagenesis (116, 130, 131).”
BackgroundGene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
Zeng, J., Nguyen, M. A., Liu, P., da Silva, L. F., Levesque, S., Lin, L. Y., Justus, D. G., Petri, K., Clement, K., Porter, S. N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.001 · Cited by 41
“…approaches for HbF induction, microRNA embedded shRNA targeting the BCL11A transcript selectively in erythroid precursors (aka BCL11A -shmiR) 7,35 , and introducing edits to the HBG1 and HBG2 promoters targeting binding sequences around position -115 that recruit BCL11A and are the site of…”
Self-citationDisruptive Technology: CRISPR/Cas-Based Tools and Approaches
Patsali, P., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00391-4 · Cited by 34
BCL11B-related disorder in two canadian children: Expanding the clinical phenotype
Prasad, M., Balci, T. B., Prasad, C., Andrews, J. D., Lee, R., Jurkiewicz, M. T., Napier, M. P., Colaiacovo, S., Sacoto, M. J. G., & Karp, N. (2020) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2020.104007 · Cited by 31
Hebert, N., Rakotoson, M. G., Bodivit, G., Audureau, É., Bencheikh, L., Kiger, L., Oubaya, N., Pakdaman, S., Sakka, M., Liberto, G. D., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25937 · Cited by 34
Embryonic and fetal human hemoglobins: structures, oxygen binding, and physiological roles
Manning, J. M., Manning, L. R., Dumoulin, A., Padovan, J. C., & Chait, B. (2020) · Subcellular Biochemistry · doi:10.1007/978-3-030-41769-7_11 · Cited by 30
“Patients with HPFH have mutations in one of the two regions that bind this repressor thus leading to incomplete termination of HbF expression (Brendel et al. 2016; Liu et al. 2018).”
BackgroundGenetic therapies for the first molecular disease
Doerfler, P. A., Sharma, A., Porter, J. S., Zheng, Y., Tisdale, J. F., & Weiss, M. J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146394 · Cited by 31
Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials
Segura, E., Ayoub, P. G., Hart, K. L., & Kohn, D. B. (2023) · Viruses · doi:10.3390/v15030713 · Cited by 35
“The β22 glutamic acid interacts with an imidazole group of the α20 histidine from an adjacent hemoglobin and plays a crucial role in HbS polymer stability.”
BackgroundMethodInfluentialGene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges
Ghiaccio, V., Chappell, M., Rivella, S., & Breda, L. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00383-4 · Cited by 31
“Lineage-specific BCL11a knockdown experiments have demonstrated amelioration of many of the sickling characteristics and toxicities normally associated with SCD [101].”
BackgroundGenome editing approaches to β-hemoglobinopathies
Brusson, M., & Miccio, A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.025 · Cited by 33
Liu, B., Brendel, C., Vinjamur, D. S., Zhou, Y., Harris, C. E., McGuinness, M. K., Manis, J. P., Bauer, D. E., Xu, H., & Williams, D. A. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.002 · Cited by 30
Self-citationRecent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications
Zhou, L., & Yao, S. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00115-5 · Cited by 33
Chambers, C. B., Gross, J., Pratt, K. L., Guo, X., Byrnes, C., Lee, Y. T., Lavelle, D., Dean, A., Miller, J. L., & Wilber, A. C. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.011 · Cited by 32
“The transcription factors B cell CLL/lymphoma 11A (BCL11A) and leukemia/ lymphoma-related factor (LRF) encoded by the ZBTB7A gene independently suppress g-globin expression in adult erythroid cells, and inhibition of either factor favors HbF production.(34,37,38) Recently, insulin-like growth factor 2 mRNA binding pro…”
BackgroundTargeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option
Starlard‐Davenport, A., Gu, Q., & Pace, B. S. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00589-z · Cited by 31
Evolution of nanobodies specific for BCL11A
Yin, M., Izadi, M., Tenglin, K., Viennet, T., Zhai, L., Zheng, G., Arthanari, H., Dassama, L. M. K., & Orkin, S. H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218959120 · Cited by 30
Self-citationAdvances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Río, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 31
Wang, F., Ling, L., & Yu, D. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.02.011 · Cited by 34
Woodard, K. J., Doerfler, P. A., Mayberry, K. D., Sharma, A., Levine, R. M., Yen, J. S., Valentine, V. A., Palmer, L. E., Valentine, M. B., & Weiss, M. J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049463 · Cited by 27
Advances in therapeutic application of CRISPR-Cas9
Sun, J., Wang, J., Zheng, D., & Hu, X. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz031 · Cited by 26
BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice
Jang, Y., Feng, R., Palmer, L. E., Mayuranathan, T., Yao, Y., Mayberry, K. D., Zhou, S., Xu, J., Gossett, J. M., Kang, G., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015574 · Cited by 25
Hodonsky, C. J., Baldassari, A., Bien, S. A., Raffield, L. M., Highland, H. M., Sitlani, C. M., Wojcik, G. L., Tao, R., Graff, M., Tang, W., et al. (2020) · BMC Genomics · doi:10.1186/s12864-020-6626-9 · Cited by 31
“Improved characterization of RBC molecular pathways has benefitted both disease diagnosis and pharmaceutical development, as has been demonstrated by recent successes in a BCL11A-silencing gene therapy clinical trial for individuals with sickle cell disease (SCD) [10, 11].”
BackgroundRecent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 29
Genome and Epigenome Editing to Treat Disorders of the Hematopoietic System
Mussolino, C., Alzubi, J., Pennucci, V., Turchiano, G., & Cathomen, T. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.149 · Cited by 24
“31 A complementary approach was successfully employed using designer endonucleases to delete a GATA-1 enhancer element present in the BCL11A gene that is required for its robust expression in the erythroid compartment.”
Brusson, M., Chalumeau, A., Martinucci, P., Romano, O., Félix, T., Poletti, V., Scaramuzza, S., Ramadier, S., Masson, C., Ferrari, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.012 · Cited by 25
Lessard, S., Rimmelé, P., Ling, H., Moran, K., Vieira, B. F., Lin, Y.-D., Rajani, G. M., Hong, V., Reik, A., Boismenu, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74716-7 · Cited by 24
“…by high indel frequency, and led to HbF induction ex vivo, in plerixafor-mobilized HSC from both healthy donors and donors with SCD. ZFN-mediated gene editing did not impact terminal erythroid differentiation, consistent with previously published approaches targeting the ESE of BCL11A 30,31,38–41 .”
BackgroundRegulated GATA1 expression as a universal gene therapy for Diamond-Blackfan anemia
Voit, R. A., Liao, X., Caulier, A., Antoszewski, M., Cohen, B., Armant, M. A., Lu, H. Y., Fleming, T. J., Kamal, E., Wahlster, L., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.012 · Cited by 23
Self-citationRapid and Sensitive Assessment of Globin Chains for Gene and Cell Therapy of Hemoglobinopathies
Loucari, C. C., Patsali, P., van Dijk, T. B., Stephanou, C., Papasavva, P. L., Zanti, M., Kurita, R., Nakamura, Y., Christou, S., Sitarou, M., et al. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.190 · Cited by 23
Venkatesan, V., Srinivasan, S., Babu, P., & Thangavel, S. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00253-20 · Cited by 26
“However, it resulted in the 440 impairment of long-term engraftment potential of mouse and human HSPCs (133).”
BackgroundA Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies
Zittersteijn, H. A., Harteveld, C. L., Klaver-Flores, S., Lankester, A. C., Hoeben, R. C., Staal, F. J. T., & Gonçalves, M. A. F. V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617780 · Cited by 24
“Before its application in a clinical setting, this LV was optimized to minimize the cytotoxicity of shRNA expression and BCL11A knock-down in HSCs (Brendel et al., 2016).”
BackgroundMethodA tetramer of BCL11A is required for stable protein production and fetal hemoglobin silencing
Zheng, G., Yin, M., Mehta, S., Chu, I.-T., Wang, S., Alshaye, A., Drainville, K., Buyanbat, A., Bienfait, F., Tenglin, K., et al. (2024) · Science · doi:10.1126/science.adp3025 · Cited by 22
Self-citationThe use of adenoviral vectors in gene therapy and vaccine approaches
Araújo, N. M., Rubio, I. G. S., Toneto, N. P. A., Morale, M. G., & Tamura, R. E. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2022-0079 · Cited by 20
“The reactivation of the fetal hemoglobin HbF coded by the gamma-globin gene by knocking out its repressor BCL-11A (Brendel et al., 2016; Li et al., 2018a) or the binding sites in the globin gene (Traxler et al.”
Gene Editing for Inherited Red Blood Cell Diseases
Bustamante, O. Q., Fañanas-Baquero, S., Dessy-Rodríguez, M., Ojeda-Pérez, I., & Segovia, J. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.848261 · Cited by 20
“As mentioned above, the generation of indels at the BCL11A gene, which suppress fetal globins, or at different positions in the β-globin locus, switches adult globin expression to fetal expression in order to compensate for defects of these diseases (Canver et al., 2015; Brendel et al., 2016; Ye et al., 2016; Holmes e…”
BackgroundInfluentialThe Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy
Orkin, S. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2405260 · Cited by 21
Self-citationIn The Blood: Connecting Variant to Function In Human Hematopoiesis
Nandakumar, S. K., Liao, X., & Sankaran, V. G. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.05.006 · Cited by 19
Nualkaew, T., Sii-Felice, K., Giorgi, M., McColl, B., Gouzil, J., Glaser, A., Voon, H. P. J., Tee, H. Y., Grigoriadis, G., Svasti, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.037 · Cited by 20
BCL11A Down-Regulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells
Li, J., Yongrong, L., & Shi, L. (2018) · Hemoglobin · doi:10.1080/03630269.2018.1515774 · Cited by 20
“on HSCs and other hematopoietic lineages [30,37].”
Gupta, A. O., Azul, M., Bhoopalan, S. V., Abraham, A., Bertaina, A., Bidgoli, A., Bonfim, C., Dezern, A. E., Li, J., Louis, C. U., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.06.002 · Cited by 17
Patsali, P., Papasavva, P. L., Stephanou, C., Christou, S., Sitarou, M., Antoniou, M. N., Lederer, C. W., & Kleanthous, M. (2018) · Haematologica · doi:10.3324/haematol.2018.189357 · Cited by 17
“High titers of shRNA-encoding vectors and constitutive expression were applied, whereas for potential clinical translation, moderate VCN and erythroid-specific shRNA expression will be required.(8) The specific mechanism of shRNA-mediated HBB induction is under investigation, with findings in MEL-HBB cells for HBB RNA…”
BackgroundMethodEmerging therapies in β-thalassemia: toward a new era in management
Bou‐Fakhredin, R., Tabbikha, R., Daadaa, H., & Taher, A. T. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1752180 · Cited by 20
“A new approach to induce HbF by silencing BCL11A involves the use of an erythroid-specific promoter to drive a microRNA-adapted short hairpin (shRNA) [56,61] Other gene-editing approaches to inhibit BCL11A that have been described and are currently in pre-clinical stages include: clustered regularly interspaced palind…”
BackgroundCombination of lentiviral and genome editing technologies for the treatment of sickle cell disease
Ramadier, S., Chalumeau, A., Félix, T., Othman, N., Aknoun, S., Casini, A., Maule, G., Masson, C., Cian, A. D., Frati, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.019 · Cited by 20
Implications of hematopoietic stem cells heterogeneity for gene therapies
Epah, J., & Schäfer, R. (2021) · Gene Therapy · doi:10.1038/s41434-021-00229-x · Cited by 18
Effective therapies for sickle cell disease: are we there yet?
Crossley, M., Christakopoulos, G. E., & Weiss, M. J. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.07.003 · Cited by 22
Shmukler, B. E., Rivera, A., Bhargava, P., Nishimura, K. K., Hsu, A., Kim, E. H., Trudel, M., Rust, M. B., Hübner, C. A., Brugnara, C., et al. (2019) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2019.102346 · Cited by 16
“Recently, inhibition of Bcl11 expression has shown great promise as the strongest inducer of HbF to date (4).”
BackgroundUchida, N., Ferrara, F., Drysdale, C. M., Yapundich, M., Gamer, J., Nassehi, T., DiNicola, J., Shibata, Y., Wielgosz, M. M., Kim, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0411 · Cited by 17
Self-citationMolecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency
Wessels, M. W., Cnossen, M. H., van Dijk, T. B., Gillemans, N., Schmidt, K. L. J., van Lom, K., Vinjamur, D. S., Coyne, S. M., Kurita, R., Nakamura, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003753 · Cited by 16
Self-citationTargeting fetal hemoglobin expression to treat β hemoglobinopathies
Steinberg, M. H. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066519 · Cited by 19
Treating Sickle Cell Disease: Gene Therapy Approaches
Cavazzana, M., Corsia, A., Brusson, M., Miccio, A., & Semeraro, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022124-022000 · Cited by 23
Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies
Bauer, D. E., Brendel, C., & Fitzhugh, C. D. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.014 · Cited by 15
Self-citationCurrent and future gene therapies for hemoglobinopathies
Brendel, C., & Williams, D. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000581 · Cited by 15
Self-citationRecent Approaches for Manipulating Globin Gene Expression in Treating Hemoglobinopathies
Mussolino, C., & Strouboulis, J. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618111 · Cited by 19
“, 2016), the recent evidence that this gene can be ablated in an erythroid-specific fashion (Brendel et al., 2016) provides a new opportunity to be explored in the epigenome editing field.”
BackgroundTranscriptional Repressor BCL11A in Erythroid Cells
Zheng, G., & Orkin, S. H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-62731-6_9 · Cited by 15
Self-citationRed Blood Cells as Therapeutic Target to Treat Sickle Cell Disease
Bhatt, S., Argueta, D. A., Gupta, K., & Kundu, S. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0348 · Cited by 15
Metadata
- Authors
- Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., Orkin, S. H., Gregory, R. I., & Williams, D. A.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Medizinische Hochschule Hannover (DE)
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-09-06
- Volume
- 126
- Issue
- 10
- Pages
- 3868-3878
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5096824
- OpenAlex
- W2513179752
- Cited by
- 167
- References
- 45
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 17 · 2023: 15 · 2022: 15 · 2021: 26 · 2020: 26 · 2019: 17 · 2018: 18 · 2017: 14 · 2016: 3
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- bluebird bio
- Centre Hospitalier Universitaire Vaudois
- National Institutes of Health (DK093705)
- National Heart, Lung, and Blood Institute (U01HL117720)
- National Institute of Diabetes and Digestive and Kidney Diseases (F30DK103359, K08DK093705)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- BCL11A, sickle cell disease, beta-thalassemia, hematopoietic engraftment, HSC exhaustion, γ-globin expression, erythroid cells, hemolytic anemia, reticulocytosis, gene therapy
- MeSH terms
- Anemia, Sickle Cell, Animals, Carrier Proteins, Cells, Cultured, Graft vs Host Disease, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mice, Inbred C57BL, Nuclear Proteins, Phenotype, Repressor Proteins, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Cell Lineage, RNA, Small Interfering, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.